Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details)

v3.20.1
Commitments and Contingencies (Details)
1 Months Ended 12 Months Ended
Aug. 29, 2019
USD ($)
Mar. 31, 2019
USD ($)
Mar. 31, 2019
CNY (¥)
Oct. 23, 2018
USD ($)
May 29, 2018
Oct. 25, 2017
Jan. 19, 2017
USD ($)
Jan. 19, 2017
CNY (¥)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Oct. 23, 2018
CNY (¥)
Joint venture agreement, description       Within 6 days of signing the AVAR Agreement, Avactis is required to pay to Arbele $300,000 as a research and development fee with an additional two payments of $300,000 (for a total of $900,000) to be paid upon mutually agreed upon milestones.              
Research and development fee                 $ 1,781,869 $ 39,061  
Line of Credit Agreement [Member]                      
Line of credit $ 20,000,000                    
Line of facility mature date Dec. 31, 2024                    
Line of Credit bears interest at an annual rate 5.00%                    
Recevied Loan                 2,600,000    
Avalon Shanghai [Member]                      
Joint venture agreement, description         Avalon Shanghai entered into a Joint Venture Agreement with Jiangsu Unicorn Biological Technology Co., Ltd. ("Unicorn"), pursuant to which a company named Epicon Biotech Co., Ltd. ("Epicon") was formed on August 14, 2018. Epicon is owned 60% by Unicorn and 40% by Avalon Shanghai. Within two years of execution of the Joint Venture Agreement, Unicorn shall invest cash into Epicon in an amount not less than RMB 8,000,000 (approximately $1.1 million) and the premises of the laboratories of Nanjing Hospital of Chinese Medicine for exclusive use by Epicon, and Avalon Shanghai shall invest cash into Epicon in an amount not less than RMB 10,000,000 (approximately $1.4 million). Epicon is focused on cell preparation, third party testing, biological sample repository for commercial and scientific research purposes and the clinical transformation of scientific achievements. As of December 31, 2019, Avalon Shanghai has contributed RMB 4,100,000 (approximately $0.6 million) that was included in equity method investment on the accompanying consolidated balance sheets.            
AVAR BioTherapeutics (China) Co. Ltd. [Member]                      
Joint venture agreement, description       Avactis Biosciences, Inc. ("Avactis"), a wholly-owned subsidiary of the Company, and Arbele Limited ("Arbele") agreed to the establishment of AVAR BioTherapeutics (China) Co. Ltd. ("AVAR"), a Sino-foreign equity joint venture, pursuant to an Equity Joint Venture Agreement (the "AVAR Agreement"), which will be owned 60% by Avactis and 40% by Arbele. The purpose and business scope of the Joint Venture is to research, develop, produce, sell, distribute and generally commercialize CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy in China. Avactis is required to contribute $10 million (or equivalent in RMB) in cash and/or services, which shall be contributed in tranches based on milestones to be determined jointly by AVAR and Avactis in writing subject to Avactis' cash reserves. Within 30 days, Arbele shall make a contribution of $6.66 million in the form of entering into a License Agreement with AVAR granting AVAR with an exclusive right and license in China to its technology and intellectual property pertaining to CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy technology and any additional technology developed in the future with terms and conditions to be mutually agreed upon Avactis and AVAR and services.              
Working capital       $ 700,000              
Research and development fee       $ 600,000              
RMB [Member] | AVAR BioTherapeutics (China) Co. Ltd. [Member]                      
Working capital | ¥                     ¥ 5,000,000
Beijing Genexosome Office Lease [Member]                      
Expiration period   Mar. 14, 2020 Mar. 14, 2020                
Lease, annual rent   $ 1,000                  
Rent expense                 802    
Lease, description   The term of this lease is one year commencing on March 15, 2019 and expired on March 14, 2020 The term of this lease is one year commencing on March 15, 2019 and expired on March 14, 2020                
Operating lease                 209    
Stock purchase agreement, description           Beijing Genexosome and Yu Zhou, MD, PhD, the sole shareholder of Beijing Genexosome, pursuant to which Genexosome acquired all of the issued and outstanding securities of Beijing Genexosome in consideration of a cash payment in the amount of $450,000 of which $100,000 is still owed. Further, on October 25, 2017, Genexosome entered into and closed an Asset Purchase Agreement with Dr. Zhou, pursuant to which the Company acquired all assets, including all intellectual property and exosome separation systems, held by Dr. Zhou pertaining to the business of researching, developing and commercializing exosome technologies. In consideration of the assets, Genexosome paid Dr. Zhou $876,087 in cash, transferred 500,000 shares of common stock of the Company to Dr. Zhou and issued Dr. Zhou 400 shares of common stock of Genexosome.          
Beijing Genexosome Office Lease [Member] | RMB [Member]                      
Lease, annual rent | ¥     ¥ 7,000                
Avalon Shanghai Office Lease [Member]                      
Lease, monthly rent             $ 7,000        
Rent expense                 $ 90,000 $ 91,000  
Security deposit             24,000        
Operating lease maintenance fees             $ 600        
Lease, description             The term of the Beijing Office Lease is 26 months commencing on January 1, 2017 and expired on February 28, 2019 with two months of free rent in the months of December 2017 and February 2019. On December 27, 2018, Avalon Shanghai signed an extension for the lease with expiration date of February 29, 2020. The term of the Beijing Office Lease is 26 months commencing on January 1, 2017 and expired on February 28, 2019 with two months of free rent in the months of December 2017 and February 2019. On December 27, 2018, Avalon Shanghai signed an extension for the lease with expiration date of February 29, 2020.      
Operating lease             $ 15,775        
Avalon Shanghai Office Lease [Member] | RMB [Member]                      
Expiration period             Feb. 29, 2020 Feb. 29, 2020      
Lease, monthly rent | ¥               ¥ 50,586      
Security deposit | ¥               164,764      
Operating lease maintenance fees | ¥               ¥ 4,336